British going-private candidate

(Full access for Lifetime Members only)

British going-private candidate

19 March 2024

The company featured in this exclusive report had a bad start when it listed over a decade ago. It failed all its targets, and the stock temporarily lost over 90% of its value.

Over the past few years, the company:

  • Replaced its leadership team.
  • Raised fresh capital.
  • Took over its largest rival.

Hardly anyone has noticed it yet, but it's now in a much-improved position:

  • Break-even achieved in 2023.
  • Growth accelerated to >20% p.a.
  • A clear path towards future growth and profitability.

This is a stock that belongs to a small, highly specialised group of companies around the world that are all directly comparable – a family of companies, so to speak. A similar company in this sector got taken out by a bid a while ago, earning its shareholders nearly three times the price compared to where the stock traded a year earlier.

The major shareholders of today's featured company have a clear financial incentive to take it private, before selling it onwards to a larger firm. For such a going-private bid to succeed, it probably needs to be 50-100% above the current price.

If the company in question doesn't go private and remains listed, it will probably be driven upwards by its newfound success. It's no longer a turnaround but a veritable growth story.

The main downside? Limited trading liquidity, due to a market cap of just about GBP 100m (USD 120m).

This opportunity is therefore exclusively available to Undervalued-Shares.com Lifetime Members.

Not a Lifetime Member yet? Sign up for a Membership - just USD 999/one-off.
Already a Lifetime Member? Log into your account to download the report.

Most recent

Latest reports (for Members only)

2-2.5x from an investment holding liquidation

2-2.5x from an investment holding liquidation

This AIM-listed small-cap will likely return all its capital to shareholders. Underresearched by investors, it's an opportunity that shouldn't even exist – but it does.

Ukraine reconstruction: one stock to benefit

Ukraine reconstruction: one stock to benefit

If or when the war in Ukraine ends, this stock will likely become the focus of investor money pushing into the country.

Actinium-225, aka "the world's rarest drug"

Actinium-225, aka "the world's rarest drug"

This little-known Western European company could become the global market leader for supplying the uber-rare "Ac-225", a potent weapon to treat cancer.